By Fineline Cube 
Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and licensing agreement to develop a next‑generation genetically engineered pertussis vaccine. The partnership will combine Olymvax’s expertise in vaccine research and Delonix’s advanced genetic‑engineering platform to accelerate the discovery, pre‑clinical development, and industrialization of a more effective and cost‑efficient pertussis immunization.
Collaboration Highlights
| Element | Details |
|---|---|
| Objective | Rapid development of a new‑generation pertussis vaccine and multivalent combined vaccines |
| Technology | Genetic‑engineering approach that preserves natural antigen epitopes and conformations while reducing manufacturing complexity |
| Benefits | Broader, more durable immune protection; lower production costs; faster time‑to‑market |
| Scope | From laboratory research through clinical trials to commercialization |
Strategic Rationale
- Leveraging Complementary Strengths – Olymvax’s proven track record in vaccine development and Delonix’s state‑of‑the‑art gene‑engineering capabilities create a synergistic platform.
- Addressing Global Public‑Health Needs – Pertussis remains a leading cause of infant morbidity and mortality worldwide; a next‑generation vaccine could dramatically reduce disease burden.
- Commercial Viability – The streamlined manufacturing process is expected to lower production costs, improving market access and pricing strategies in both emerging and developed markets.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech